PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE
    1.
    发明申请

    公开(公告)号:US20180201654A1

    公开(公告)日:2018-07-19

    申请号:US15727472

    申请日:2017-10-06

    申请人: Jae Jung

    发明人: Jae Jung

    IPC分类号: C07K14/005 A61K38/16

    摘要: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL.

    PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE
    2.
    发明申请
    PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE 审中-公开
    HAUSP DEUBIQUITINASE的肽抑制剂

    公开(公告)号:US20140073585A1

    公开(公告)日:2014-03-13

    申请号:US13971744

    申请日:2013-08-20

    申请人: Jae Jung

    发明人: Jae Jung

    IPC分类号: C07K14/005

    摘要: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL.

    摘要翻译: 对应于vIRF4的aa202-216的vIRF4(卡波西 - 肉瘤相关疱疹病毒vIRF4)肽vif1和对应于vIRF4的a220-236的vif2是有效和选择性的HAUSP拮抗剂。 vif1和vif2肽强力抑制HAUSP DUB酶活性,最终导致p53介导的抗癌活性。 vif1和vif2肽及其同源物可用于治疗ALL。